Our primary indication is for glioblastoma, because we understand the metabolic vulnerabilities of these cancer cells and because patients with glioblastoma have few other options right now.

 

Glioma is the most common form of primary malignant brain tumor. This cancer often presents as a high-grade (stage four) cancer called glioblastoma, with a dire prognosis and few therapeutic options. Approximately 15,000 patients are diagnosed with glioma each year in the United States, and approximately 250,000 patients are diagnosed each year world-wide.

​

Over the past seventy years, hundreds of drugs have been designed to target oncogenic pathways in glioma, or repurposed after successes with other cancers. Yet nearly all of these options have failed at clinical trial.

 

The current standard-of-care for glioma patients comprises surgical resection of the tumor to the extent possible, radiotherapy, and the chemotherapeutic drug temozolomide. Together, these existing therapies only minimally slow the course of this disease, raising the median survival time for patients with glioblastoma from 12.1 months to 14.6 months.

 

New treatments are desperately needed to increase the survival and quality of life for this patient population. We believe that by deeply understanding the biology of these tumors, we can better target the cancer cells and make a positive difference in patients' lives.